๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Zhengzhou 39 Anyang 3 Jiaozuo 3 Kaifeng 3 Jiyuan 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital72 The First Affiliated Hospital of Zhengzhou University39 Merck Sharp & Dohme LLC27 AbbVie21 Novartis Pharmaceuticals20 Clear sponsor filter
Site location
Zhengzhou39 Anyang3 Jiaozuo3 Kaifeng3 Jiyuan2
All 29 locations
Target enrolment
to

Trials with a site in Zhengzhou

39 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
NCT07828873Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2
34
Zhengzhou
2026-11
Not yet open
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
NCT07769658Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Not yet open
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
NCT07814859Pancreatic Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
88
Zhengzhou
2026-08-31
Not yet open
Pro-urokinase for Extended-Window Posterior Circulation Stroke
NCT07617870Acute Ischemic Stroke
The First Affiliated Hospital of Zhengzhou University
Phase 3
586
Zhengzhou
2026-06-01
Not yet open
Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch
NCT07540416Acute Ischemic Stroke
The First Affiliated Hospital of Zhengzhou University
Phase 3
564
Zhengzhou
2026-05-01
Not yet open
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
NCT07446335Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 3
578
Zhengzhou
2026-04
Not yet open
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
NCT07361991Advan'ce'd, Advanced
The First Affiliated Hospital of Zhengzhou University
Phase 1/2
50
Zhengzhou
2026-03
Not yet open
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
NCT05114941Guillain-Barre Syndrome
The First Affiliated Hospital of Zhengzhou University
Not applicable
204
Zhengzhou
2026-01-01
Not yet open
Prospective, Multicenter, Single-Arm, Phase โ…ก Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
NCT07314619Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University
Phase 2
30
Zhengzhou
2025-12-30
Recruiting
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ยฑ Adebrelimab in Treating Advanced Second-line Gastric Cancer
NCT07770113GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2025-06-30
Recruiting
PDL1/TGFฮฒ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
NCT07294664Advanced Gastric Cancer, SHR1701
The First Affiliated Hospital of Zhengzhou University
Phase 2
78
Zhengzhou
2025-06-15
Active, closed
Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network
NCT07203495Lung Diseases, Endocrine Diseases, Gastrointestinal Diseases
The First Affiliated Hospital of Zhengzhou University
Observational
200
Zhengzhou
2025-06-01
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06559345Acute Lymphoblastic Leukemia, Pediatric
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-17
Recruiting
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
NCT07104149Female, Age โ‰ฅ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
The First Affiliated Hospital of Zhengzhou University
Phase 2
29
Zhengzhou
2025-03-10
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
NCT06564545Acute Lymphoblastic Leukemia, Adult
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-01
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06564493Acute Lymphoblastic Leukemia, Pediatric
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
NCT06557161Acute Lymphoblastic Leukemia, Adult
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Recruiting
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
NCT06930573HCC
The First Affiliated Hospital of Zhengzhou University
Phase 4
30
Zhengzhou
2024-12-04
By invitation
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
NCT06901622Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2024-11-08
Recruiting
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
NCT07599371Relapsed/Refractory Glioma
The First Affiliated Hospital of Zhengzhou University
Phase 1/2
29
Zhengzhou
2024-10-10
Recruiting
Energy CT in Imaging and Diagnosis of Gastric Cancer
NCT06869694Gastric Cancer, CT
The First Affiliated Hospital of Zhengzhou University
Observational
300
Zhengzhou
2024-09-01
Recruiting
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
NCT07016724Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2
208
Zhengzhou
2024-08-15
By invitation
Effects of ITBS Combined with NMES on Dysphagia After Stroke
NCT06464835Stroke, Dysphagia, Intermittent Theta Burst Stimulation, Neuromuscular Electrical Stimulation
The First Affiliated Hospital of Zhengzhou University
Not applicable
45
Zhengzhou
2024-08-03
Not yet open
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
NCT06492317HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
20
Zhengzhou
2024-07-06
Recruiting
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
NCT06747728Brain Glioma
The First Affiliated Hospital of Zhengzhou University
Not applicable
20
Zhengzhou
2024-03-01
Recruiting
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT06718205Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Recruiting
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
NCT05738434Esophageal Cancer by AJCC V8 Stage
The First Affiliated Hospital of Zhengzhou University
Phase 2
188
Zhengzhou
2023-03-02
Recruiting
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
NCT05286957NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2
60
Zhengzhou
2022-06-20
Recruiting
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
NCT05182944Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
130
Zhengzhou
2022-01-15
Recruiting
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT03736863Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
147
Zhengzhou
2019-12-05
Recruiting
MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence
NCT04215211Glioma
The First Affiliated Hospital of Zhengzhou University
Observational
2,500
Zhengzhou
2017-01-01
Recruiting
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
NCT04217044Glioma
The First Affiliated Hospital of Zhengzhou University
Observational
3,000
Zhengzhou
2017-01-01
Recruiting
Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
NCT04215224Glioma
The First Affiliated Hospital of Zhengzhou University
Observational
3,500
Zhengzhou
2017-01-01
Recruiting
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
NCT04217018Glioma
The First Affiliated Hospital of Zhengzhou University
Observational
3,000
Zhengzhou
2017-01-01
Recruiting
Azoospermia Patients
NCT03991663Healthy Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
Primary Ovarian Insufficient Patients
NCT03989154Healthy Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
Newborns From Patients Treated With ART (Assisted Reproductive Technology)
NCT03993158Health Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Recruiting
PCOS (Polycystic Ovarian Syndrome) Patients
NCT03991507Health Related
The First Affiliated Hospital of Zhengzhou University
Observational
10,000
Zhengzhou
2010-01-01
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

26 of the 39 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 1 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 39 studies
PhaseStudiesRecruitingShare
Phase 2181346.2%
Observational11928.2%
Not applicable317.7%
Phase 3307.7%
Phase 1/2215.1%
Phase 1112.6%
Phase 4112.6%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Zhengzhou University3926
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.